Technical Analysis for KZIA - Kazia Therapeutics Limited - American Depositary Shares

Grade Last Price % Change Price Change
grade D 4.06 0.44% 0.02
KZIA closed up 0.44 percent on Friday, February 21, 2020, on 33 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Flat
Historical KZIA trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Bollinger Band Squeeze Range Contraction 0.44%
BB Squeeze Started Range Contraction 0.44%
Inside Day Range Contraction 0.44%
BB Squeeze Ended Range Expansion 2.78%
Lower Bollinger Band Touch Weakness 2.78%
20 DMA Resistance Bearish -0.31%
Bollinger Band Squeeze Range Contraction -0.31%
NR7 Range Contraction -0.31%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Biotechnology Cancer Organ Systems ATM Chemotherapy Ovarian Cancer Neuroblastoma Glioma Pharmaceutical Research Diffuse Intrinsic Pontine Glioma

Is KZIA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.74
52 Week Low 2.24
Average Volume 17,475
200-Day Moving Average 3.38
50-Day Moving Average 4.28
20-Day Moving Average 4.13
10-Day Moving Average 4.06
Average True Range 0.22
ADX 17.95
+DI 16.30
-DI 22.77
Chandelier Exit (Long, 3 ATRs ) 3.78
Chandelier Exit (Short, 3 ATRs ) 4.47
Upper Bollinger Band 4.35
Lower Bollinger Band 3.92
Percent B (%b) 0.33
BandWidth 10.48
MACD Line -0.07
MACD Signal Line -0.06
MACD Histogram -0.0095
Fundamentals Value
Market Cap 19.61 Million
Num Shares 4.83 Million
EPS -1.80
Price-to-Earnings (P/E) Ratio -2.26
Price-to-Sales 2.05
Price-to-Book 0.71
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.26
Resistance 3 (R3) 4.25 4.18 4.22
Resistance 2 (R2) 4.18 4.13 4.18 4.21
Resistance 1 (R1) 4.12 4.10 4.09 4.13 4.20
Pivot Point 4.05 4.05 4.03 4.05 4.05
Support 1 (S1) 3.99 4.00 3.96 4.00 3.92
Support 2 (S2) 3.92 3.97 3.92 3.91
Support 3 (S3) 3.86 3.92 3.90
Support 4 (S4) 3.87